Evidence map›Paper›PMID 23866070›Full record

ArticleCardiovascular diabetology2013

Plasma levels of the arterial wall protein fibulin-1 are associated with carotid-femoral pulse wave velocity: a cross-sectional study.

Esben Laugesen, Pernille Høyem, Jens Sandahl Christiansen, Søren Tang Knudsen, Klavs Würgler Hansen, W Scott Argraves, Troels Krarup Hansen, Per Løgstrup Poulsen, Lars Melholt Rasmussen

Registry-linked trialAbstract read
In one paragraph

Article in Cardiovascular diabetology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02001532 (Arterial Stiffness and Complication Risk in Type 2 Diabetes), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02001532 completednot on this mapstarted 2014, after this paper: background citation

Arterial Stiffness and Complication Risk in Type 2 Diabetes

TypeobservationalSponsorAarhus University HospitalRan2014 to 2016Enrolled140ConditionsDiabetes Mellitus, Type 2, Diabetes Complications, Diabetic Angiopathies, Diabetic Nephropathies
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Esben Laugesen
Pernille Høyem
Jens Sandahl Christiansen
Søren Tang Knudsen
Klavs Würgler Hansen
W Scott Argraves
Troels Krarup Hansen
Per Løgstrup Poulsen
Lars Melholt Rasmussen

Funding

Fibulin-1 Regulation of the DiGeorge Syndrome Pathogenesis PathwayR01HL095067 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ARGRAVES, WILLIAM SCOTT · 2009 to 2012
$1.5M
NHLBI NIH HHS HL095067
6 · The paper itself

Abstract

backgroundThe arterial system in diabetic patients is characterized by generalized non-atherosclerotic alterations in the vascular extracellular matrix causing increased arterial stiffness compared with subjects without diabetes. The underlying pathophysiology remains elusive. The elastin-associated extracellular matrix protein, fibulin-1, was recently found in higher concentrations in the arterial wall and in plasma in patients with long duration type 2 diabetes. Furthermore, plasma fibulin-1 independently predicted total mortality and was associated with pulse pressure, an indirect measure of arterial stiffness. Whether plasma fibulin-1 is associated with arterial stiffness at earlier phases of type 2 diabetes has not been determined.

methodsIn this cross-sectional study, we examined 90 patients with recently diagnosed type 2 diabetes (< 5 years) and 90 gender- and age-matched controls. Plasma fibulin-1 was measured immunochemically. Arterial stiffness was assessed by carotid-femoral Pulse Wave Velocity (PWV). Differences in means were assessed by t-tests. Associations were assessed by multivariate regression analyses.

resultsPlasma fibulin-1 levels were lower in the diabetic group compared with the control group, 93 ± 28 vs 106 ± 30 μg/mL, p = 0.005. In unadjusted analysis of the total study sample, plasma fibulin-1 was not associated with PWV, p = 0.46. However, with adjustment for the confounders age, gender, mean blood pressure, heart rate, body mass index, diabetes and glomerular filtration rate, a 10 μg/mL increase in plasma fibulin was associated with 0.09 ± 0.04 m/s increase in PWV, p < 0.05. In subgroup analysis, plasma fibulin-1 was associated with PWV in the diabetes group, (0.16 ± 0.07 m/s increase in PWV per 10 μg/mL increase in plasma fibulin-1, p<0.05), but not controls, β = 0.021 ± 0.057 m/s per 10 μg/mL, p = 0.70. The association remained significant in the diabetes group after adjustment for covariates, p < 0.05.

conclusionsPlasma fibulin-1 is independently associated with PWV. Yet, as the plasma level of fibulin-1 was lower in patients with recently diagnosed type 2 diabetes than in healthy controls, plasma fibulin-1 levels are not a simple marker of the degree of arterial stiffening. Further studies are needed to determine the exact role of fibulin-1 in arterial stiffness and cardiovascular risk in patients with type 2 diabetes.

Indexed as

Pulse Wave AnalysisVascular StiffnessAgedBiomarkersCalcium-Binding ProteinsCarotid ArteriesCase-Control StudiesCross-Sectional StudiesDiabetes Mellitus, Type 2Diabetic AngiopathiesFemoral ArteryHumansImmunoassayMaleMiddle AgedMultivariate AnalysisBiomarkersCalcium-Binding Proteinsfibulin

Identifiers

PMID23866070
PMCPMC3722025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.